|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.50 USD | -0.94% |
|
+0.10% | -28.81% |
| Jun. 02 | Daxor Says Received US Patent for Remote Blood Volume Monitor Technology | MT |
| Apr. 26 | 5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026. | CI |
| Market Cap | 61.77M 53.99M 49.93M 45.82M 86.72M 5.95B 88.22M 595M 234M 2.91B 232M 227M 10.03B | P/E 2026 * |
-50.5x | P/E 2027 * | -353x |
|---|---|---|---|---|---|
| Enterprise Value | 61.77M 53.99M 49.93M 45.82M 86.72M 5.95B 88.22M 595M 234M 2.91B 232M 227M 10.03B | EV / Sales 2026 * |
5.19x | EV / Sales 2027 * | 2.97x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | +1.05% | ||
| Current month | +2.96% | ||
| 1 month | +9.62% | ||
| 3 months | +12.41% | ||
| 6 months | -22.63% | ||
| Current year | -28.14% |
| 1 week | 10.11 | 11.19 | |
| 1 month | 9.37 | 11.19 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2012-12-31 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 2018-09-27 |
Linda Cooper
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 1988-12-31 |
| Chairman | 56 | 2017-02-13 | |
| Director/Board Member | 61 | 2017-02-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.94% | +0.10% | +11.58% | +8.72% | 61.77M | ||
| -1.65% | -3.09% | +17.61% | +98.03% | 14.5B | ||
| -3.05% | -6.25% | +41.14% | +112.13% | 11.71B | ||
| +1.04% | +2.20% | -4.88% | +34.02% | 9.18B | ||
| +0.46% | -1.53% | -12.85% | -12.57% | 7.55B | ||
| -2.19% | -4.49% | +27.14% | +110.15% | 7.4B | ||
| -2.27% | -1.72% | +16.11% | +59.74% | 6.57B | ||
| +0.77% | +2.49% | +13.50% | +27.78% | 4.83B | ||
| +0.09% | +1.48% | +14.13% | +8.97% | 4.16B | ||
| 0.00% | +1.37% | - | - | 3.83B | ||
| Average | -0.81% | +0.34% | +13.72% | +49.66% | 7.75B | |
| Weighted average by Cap. | -1.10% | -0.12% | +15.56% | +65.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.4M 9.62M 8.83M 16.71M 1.15B 17M 115M 45.07M 560M 44.69M 43.71M 1.93B | 20.8M 18.18M 16.81M 15.43M 29.2M 2B 29.71M 201M 78.77M 979M 78.11M 76.4M 3.38B |
| Net income | -1.2M -1.05M -970K -890K -1.68M -116M -1.71M -11.57M -4.54M -56.47M -4.51M -4.41M -195M | -200K -175K -162K -148K -281K -19.27M -286K -1.93M -757K -9.41M -751K -735K -32.49M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-16 | $10.50 | -0.94% | 432 |
| 26-07-15 | $10.60 | -0.47% | 1,817 |
| 26-07-14 | $10.65 | +5.34% | 1,398 |
| 26-07-13 | $10.11 | -3.99% | 378 |
| 26-07-10 | $10.53 | +4.15% | 228 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.60USD
Average target price
22.50USD
Spread / Average Target
+112.26%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















